Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.50 |
| ▸ | CCR8 | P51685 | 1/20 | 0.50 |
| ▸ | TGFBR1 | P36897 | 12/20 | 0.44 |
| ▸ | GRM5 | P41594 | 2/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30775055 | 0.82 | KDM4E (0.48) | GRM5RAB9AKDM4EALDH1A1HPGD | |
| SCHEMBL3385678 | 0.82 | KDM4E (0.48) | GRM5RAB9AKDM4EALDH1A1HPGD | |
| SCHEMBL2473544 | 0.81 | DHODH (0.40) | CCR1CCR8TGFBR1GRM5CYP2A6 | |
| SCHEMBL2473782 | 0.79 | KMO (0.38) | TGFBR1RAB9AKDM4E | |
| SCHEMBL610009 | 0.79 | PIN1 (0.49) | KDM4EALDH1A1 | |
| SCHEMBL29077608 | 0.78 | CCR1 (0.44) | CCR1CCR8TGFBR1CYP2A6RAB9A | |
| SCHEMBL19207150 | 0.76 | TGFBR1 (0.47) | CCR1CCR8TGFBR1TGFBR2KDM4E | |
| SCHEMBL264270 | 0.76 | HCRTR2 (0.50) | KDM4EALDH1A1 | |
| SCHEMBL30775045 | 0.76 | HCRTR2 (0.50) | KDM4EALDH1A1 | |
| SCHEMBL6609571 | 0.76 | ALDH1A1 (0.58) | CCR1CCR8TGFBR1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144760-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-06-10 | — | — | US | disclosed |
| US-20100144760-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-06-10 | — | — | US | disclosed |
| WO-2010063663-A1 | N-{[(IR,4S,6R-3-(2-PYRIDINYLCARBONYL)-3-AZABICYCLO [4.1.0]HEPT-4-YL] METHYL}-2-HETEROARYLAMINE DERIVATIVES AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144760-A1 | NOVEL COMPOUNDS | HTR3B, HTR1B, HTR2B | CCR1 3456/4885CCR8 2661/4885TGFBR1 4264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.